Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 43,502 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the sale, the chief financial officer now owns 70,629 shares of the company’s stock, valued at $12,492,857.52. The trade was a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The stock was sold at an average price of $176.60, for a total value of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
- On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
Natera Trading Down 1.3 %
Shares of Natera stock opened at $174.24 on Wednesday. The firm has a market cap of $23.00 billion, a PE ratio of -99.00 and a beta of 1.66. Natera, Inc. has a 1 year low of $66.68 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a fifty day moving average price of $167.26 and a 200-day moving average price of $139.52.
Analyst Ratings Changes
NTRA has been the subject of a number of recent analyst reports. Leerink Partners increased their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Guggenheim lifted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Sanford C. Bernstein boosted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $165.88.
View Our Latest Analysis on NTRA
Hedge Funds Weigh In On Natera
Several institutional investors and hedge funds have recently bought and sold shares of NTRA. Principal Securities Inc. lifted its position in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after buying an additional 59 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock valued at $574,000 after purchasing an additional 61 shares during the last quarter. Silver Oak Securities Incorporated boosted its position in Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after purchasing an additional 89 shares during the period. Covestor Ltd increased its stake in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. 99.90% of the stock is owned by institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
- Five stocks we like better than Natera
- What is a Bond Market Holiday? How to Invest and Trade
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- How to Choose Top Rated Stocks
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- Do ETFs Pay Dividends? What You Need to Know
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.